Ovascience (OVAS) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
OvaScience Reports Second Quarter 2015 Financial Results
August 10, 2015 4:01 PM EDT- Healthy Babies Born with AUGMENT Fertility Treatment; IVF Clinics in New International Regions Offer AUGMENT Treatment -
- 2015 Plans for OvaPrime and OvaTure Treatments on Track -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported second quarter 2015 financial results and highlighted recent accomplishments, including additional healthy births with the AUGMENTSM treatment at all clinics currently offering the treatment. In addition, the AUGMENT treatment will be... More
